Compare Levi Strauss & Co. (LEVI) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Levi Strauss & Co. vs Natera Inc. Common Stock — how do they compare? Levi Strauss & Co. trades at $19.56 (market cap $7.47B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Natera Inc. Common Stock is far larger — about 7.6× Levi Strauss & Co.'s market cap, and Levi Strauss & Co. pays a 3.29% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Levi Strauss & Co. for 71 Days and Natera Inc. Common Stock for 0 Days on average.
| LEVI | NTRA | |
|---|---|---|
Market Cap | $7.47B | $57.03B |
Volume | 6,427,839 | 1,131,157 |
Sector | Consumer Cyclical | Health |
52-Week High | $25.53 | $425.64 |
52-Week Low | $17.92 | $179.42 |
Typical Hold Time | 71 Days | 0 Days |
Enterprise Value | $9.02B | $56.18B |
Dividend Yield | 3.29% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Levi Strauss (LEVI) trades at $19.57, up 1.72% with strong fundamentals including a 12.82 P/E ratio and 25.76% ROE. The stock shows bearish technical signals but has consistently beaten earnings expectations for four consecutive quarters. Recent news highlights the company's successful '90s fashion revival and appointment of a new CFO, while analyst consensus remains strongly bullish with a $29 price target representing 48% upside potential.
The investment case balances attractive valuation against technical weakness. Strong profitability metrics and consistent earnings beats support upside, but bearish technical indicators and execution risks in the competitive apparel sector warrant caution. The 78.95% buy rating from analysts suggests significant institutional confidence in Levi's growth trajectory despite near-term market sentiment concerns.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Levi Strauss & Co.
Levi Strauss & Co is involved in designing, marketing, and selling products that include jeans, casual and dresses pants, tops, shorts, skirts, jackets, footwear, and related accessories directly or through third parties and licensees for men, women, and children under Levi's, Dockers, Signature by Levi Strauss & Co. and Denizen brands. The company manages its business according to three regional segments: the Americas, which is the key revenue driver
Read more on LEVI →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
